1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Alios Purchase Boosts J&J Anti-Infectives Game, Especially Hep C

A pair of promising preclinical nucleoside polymerase inhibitors for hepatitis C might be the driving force behind J&J’s $1.75 billion buyout of Alios, even though the privately held biotech’s most advanced candidate, ALS-8176, in Phase II for respiratory syncytial virus, also is a fit for J&J’s anti-infective strategy.

Johnson & Johnson sees Alios BioPharma Inc. as a perfect fit for advancing its anti-infective drug-development strategy, with a Phase II candidate for respiratory syncytial virus and a pair of preclinical hepatitis C compounds that bolster the commercial viability of the pharma’s hepatitis C blockbuster Olysio (simeprevir).

The twin primary areas of focus for Janssen Pharmaceutical Cos.’s drug development strategy in infectious diseases are respiratory infection...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from United States

Aurobindo Expects US FTC Will Allow Lannett Acquisition

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will meet US FTC standards after an attempt to acquire Sandoz assets was nixed in 2020. The deal also could widen Aurobindo’s US manufacturing presence.

Inside Elamipretide’s CRL: Clinical And Surrogate Evidence Deficiencies, And A Path Forward

 
• By Sue Sutter

The Pink Sheet takes an exclusive look at the complete response letter, which shows the information on application deficiencies that could become widely available if FDA leaders succeed in releasing CRLs in real time.

Lilly’s Price Deal For Mounjaro In UK A Harbinger Of The MFN Future?

 
• By Cathy Kelly

The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.

Prasad’s Return Shelves Center Consolidation, But Maybe An Opening For OCE 2.0?

 
• By Kate Rawson

Vinay Prasad’s exit from the US FDA reignited conversations about integrating its drugs and biologics centers under George Tidmarsh. Those plans appear to be shelved, but the leadership transition could be an opportunity to fully realize the vision for the Oncology Center of Excellence.

More from North America